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Microsomal prostaglandin E synthase-1 (mPGES-1) is an inducible enzyme situated
downstream of cyclo-oxygenase-2, promoting the excessive PGE2 production in
inflammation. Dexamethasone is known to suppress mPGES-1 but the mechanisms
regulating mPGES-1 expression remain poorly known. MKP-1 is a phosphatase
controlling the proinflammatory MAP kinase pathways p38 and JNK, thus limiting
the inflammatory responses. We have now investigated the role of MKP-1 and MAP
kinases p38 and JNK in the regulation of mPGES-1 expression by dexamethasone.
Dexamethasone increased MKP-1 and decreased mPGES-1 expression in J774
macrophages and in peritoneal macrophages from wild-type but not from MKP-1
deficient mice. Dexamethasone also reduced p38 and JNK phosphorylation along with
enhancement of MKP-1, while inhibition of JNK reduced mPGES-1 expression. These
findings were also translated to in vivo conditions as dexamethasone downregulated
mPGES-1 expression in paw inflammation in wild-type but not in MKP-1 deficient
mice. In conclusion, dexamethasone was found to downregulate mPGES-1 expression
through enhanced MKP-1 expression and reduced JNK phosphorylation in inflammatory
conditions. The results extend the understanding on the regulation of mPGES-1
expression and highlight the potential of MKP-1 as an anti-inflammatory drug target.
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INTRODUCTION
Microsomal prostaglandin E synthase-1 (mPGES-1) is a terminal enzyme catalyzing the synthesis
of prostaglandin E2 (PGE2), an essential prostanoid linked to pathophysiological conditions, such
as inflammation, pain, fever and tumorigenesis (Samuelsson et al., 2007; Stables and Gilroy,
2011; Coulombe et al., 2014; Ruan and So, 2014; Koeberle and Werz, 2015). Two other PGE2
synthesizing enzymes have been characterized so far, namelymicrosomal prostaglandin E synthase-
2 (mPGES-2) and cytosolic prostaglandin E synthase (cPGES). Constitutively expressed mPGES-2
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and cPGES are presumed to be responsible for physiological
PGE2 formation, whereas mPGES-1 is an inducible enzyme, the
expression of which is induced under inflammatory conditions in
various cells and tissues (Samuelsson et al., 2007).
The anti-inflammatory effects of non-steroidal anti-
inflammatory drugs (NSAIDs) are considered to be based
predominantly on reduced formation of PGE2 due to inhibition
of cyclo-oxygenase (COX) enzymes. However, the known adverse
effects of NSAIDs, such as gastrointestinal, cardiovascular and
renal problems are also linked to the same mechanism of action,
that is, inhibition of cyclo-oxygenases, restricting the use of
NSAIDs among many patient groups. For example, the increased
risk of myocardial infarction may in part reflect the reduced
formation of prostacyclin (prostaglandin I2, PGI2) following
inhibition of COX-2 in the vascular wall, while mucosal erosions
and bleedings in the gastrointestinal track are considered to
result from decreased formation of protective physiological
prostanoids after inhibition of COX enzymes (Cheng et al., 2006;
Grosser et al., 2010; Coxib and traditional, NSAID Trialists’
(CNT) Collaboration, et al., 2013).
Such observations could indicate that mPGES-1 is therefore
a potential drug target for treating inflammatory conditions
and pain by selectively decreasing PGE2 production under
inflammatory conditions. An inhibitor of mPGES-1 activity or
expression could thus lead to a selective decrease of excessive
PGE2 formation during inflammation since the synthesis of other
prostanoids are not reduced similarly, as under the treatment
with NSAIDs; furthermore, the constitutive PGE2 synthesis
through mPGES-2 and cPGES remains unchanged. Moreover,
it has been reported that genetic deletion or pharmacological
inhibition of mPGES-1 may also lead to an increased production
of prostanoids exhibiting anti-inflammatory properties (Idborg
et al., 2013) and possibly modulate platelet function during
inflammation (Raouf et al., 2016). Overall, inhibition of mPGES-
1 may therefore result in therapeutic activity comparable to
NSAIDs but with less adverse effects (Samuelsson et al., 2007;
Korotkova and Jakobsson, 2013; Koeberle and Werz, 2015).
Inhibitors of mPGES-1 activity are indeed under
development. Recently, a phase I trial with the selective
mPGES-1 inhibitor LY3023703 indicated a decreased level of
a urinary metabolite of PGE2 to an extent comparable to that
caused by the COX-2 inhibitor celecoxib. In addition, a more
favorable effect on the production of prostanoids other than
PGE2 was found (Jin et al., 2015). Development of mPGES-1
inhibitors currently appears to be focused on molecules affecting
the activity of mPGES-1 and subsequent PGE2 production
(Chang and Meuillet, 2011; Korotkova and Jakobsson, 2013;
Koeberle and Werz, 2015; Chandrasekhar et al., 2016; Gupta
and Aparoy, 2016; Koeberle et al., 2016). However, as presented
in this study, an alternative approach might be to focus on
the downregulation of the expression of mPGES-1 rather than
directly affecting the activity of the enzyme.
Mitogen activated protein (MAP) kinases, namely
extracellular signal-regulated kinase (ERK), p38MAP-kinase and
c-Jun N-terminal kinase (JNK), regulate the cellular response
to various extracellular inflammatory stimuli (Johnson and
Lapadat, 2002; Raman et al., 2007). These enzymes are activated
by phosphorylation and play an essential role in the promotion
of inflammatory responses and innate immune system (Kramer
et al., 1996; Ashwell, 2006; Rincon and Davis, 2009; Plotnikov
et al., 2011; Korhonen and Moilanen, 2014). Mitogen-activated
protein kinase phosphatases (MKPs) inactivate MAP kinases
through dephosphorylation and form a negative feedback system
for the activity of MAP kinases, thus controlling and limiting the
inflammatory reaction and innate immune responses (Chi et al.,
2006; Hammer et al., 2006; Zhao et al., 2006;Wang and Liu, 2007;
Li et al., 2009;Wancket et al., 2012). MKP-1 is the most studied of
MKP enzymes and it has been shown to dephosphorylate MAP
kinases p38 and / or JNK, depending on the cell type, and thereby
decreasing the expression of many MAP kinase-dependent
pro-inflammatory factors (Franklin and Kraft, 1997; Franklin
et al., 1998; Chi et al., 2006; Zhao et al., 2006; Turpeinen et al.,
2010, 2011; Comalada et al., 2012). MKP-1 has been identified
as a mediator of some anti-inflammatory effects of drugs such
as the glucocorticoids, the anti-rheumatic drug aurothiomalate,
phosphodiesterase 4 inhibitors (Kassel et al., 2001; Abraham
et al., 2006; Nieminen et al., 2010; Shipp et al., 2010; Korhonen
et al., 2013; Keränen et al., 2017) and recently, also β2-agonists
(Keränen et al., 2016). In addition, inflammatory responses
have been found to be more severe and even lethal in MKP-1
knock-out mice as compared to wild-type controls (Chi et al.,
2006; Zhao et al., 2006; Frazier et al., 2009; Korhonen et al., 2011,
2013), emphasizing the role of MKP-1 as a limiting factor in
inflammation.
Mechanisms regulating the expression of mPGES-1 are not
fully known, but one of the few drugs found to inhibit the
expression of mPGES-1 is the glucocorticoid dexamethasone
(Stichtenoth et al., 2001), known also to enhance the expression
of MKP-1 (Kassel et al., 2001; Abraham et al., 2006; Shipp et al.,
2010). Therefore, we tested the hypothesis that dexamethasone
inhibits the expression of mPGES-1 via an elevated MKP-1
expression and subsequent dephosphorylation of MAP kinases,
by using the J774macrophage cell line and confirmed the findings
by using peritoneal macrophages from MKP-1 deficient and
corresponding wild-type mice. To evaluate the significance of
these findings in vivo, the effects of dexamethasone on the
expression of mPGES-1 in mouse paw inflammation in MKP-1
deficient and corresponding wild-type mice was also studied.
MATERIALS AND METHODS
Materials
Dexamethasone was received from Orion Corp. (Espoo,
Finland). Lipopolysaccharide (LPS) from Escherichia coli strain
0111:B4 and all other reagents were purchased from Sigma-
Aldrich Inc. (St. Louis, MO, USA) unless otherwise stated.
Animals
Wild-type and MKP-1(-/-) C57BL/6 mice originally generated
in the laboratory of R. Bravo at Bristol-Myers Squibb
Pharmaceutical Research Institute (Princeton, NJ, USA)
were used in the present study. Mice were bred at the animal
facilites in Faculty of Medicine and Life Sciences, University
of Tampere under standard conditions (12:12 light-dark cycle,
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+22± 1◦C temperature, 50–60% humidity), and food and water
provided ad libitum. Animal experiments were carried out in
accordance with the legislation for the protection of animals
used for scientific purposes (Directive 2010/63/EU), and the
study was approved by the National Animal Experiment Board.
Lipopolysaccharide-Induced Paw Edema
Lipopolysaccharide [50 µl of 2 mg/ml in phosphate-buffered
saline (PBS)] was injected into the hind paw of anesthetized mice
(0.5mg/kg, Domitor R©; OrionOyj, Espoo, Finland, and 75mg/kg,
Ketalar R©; Pfizer Oy Animal Health, Helsinki, Finland). The
contralateral paw was injected with the corresponding volume of
endotoxin-free PBS. Mice were treated 1 h prior to the injection
of LPS with dexamethasone (2 mg/kg intraperitoneally) or with
vehicle (PBS). Paw volumes were measured up to 6 h with a
plethysmometer (Ugo Basile, Comerio, Italy) and compared to
the baseline value. After the last measurement mice were sacrified
(cervical dislocation) and paw tissues were collected into RNA
Later solution (Invitrogen, Carlsbad, CA, USA).
Cell Culture
J774 mouse macrophages (American Type Culture Collection,
Rockville Pike, MD, USA ) were cultured at +37◦C in 5% CO2
atmosphere in Dulbecco’s Modified Eagle’s medium (DMEM,
Invitrogen, Paisley, UK) containing 10% (v/v) heat-inactivated
fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml
streptomycin and 250 ng/ml amphotericin B (all from Gibco,
Wien, Austria). Cells (2.5× 105 per well) were seeded on 24-well
plates and the cell monolayers were grown for 72 h prior to the
experiments. SP600125 and SB203580 were dissolved in dimethyl
sulfoxide (DMSO), dexamethasone and LPS in PBS. LPS and the
compounds under investigation in concentrations indicated or
the solvent (DMSO, final concentration 0.1% v/v in all wells)
were added to the cells in fresh culture medium containing 10%
FBS and the supplements, and the incubations were continued
for the time indicated before removing the culture medium and
harvesting the cells.
Mouse peritoneal macrophages were obtained by
peritoneal lavage with sterile PBS supplemented with 0.2
mM ethylenediaminetetraacetic acid (EDTA). Cells were washed
and seeded on 24-well plates (1 × 106 cells/well) in RPMI
medium supplemented with 2% FBS, 100 U/ml penicillin, 100
µg/ml streptomycin and 250 ng/ml amphotericin B. Cells were
incubated overnight, washed and treated with the compounds
under investigation for the period indicated.
Preparation of Cell Lysates and Western
Blot Analysis
At the indicated time points, the culture medium was
removed and the cells were washed with ice-cold PBS and
solubilized in cold lysis buffer containing 10 mM Tris–
HCl, 5mM EDTA, 50mM NaCl, 1% Triton X-100, 0.5mM
phenylmethylsulfonyl fluoride, 1mM sodium orthovanadate,
20mg/ml leupeptin, 50 mg/ml aprotinin, 5 mM sodium
fluoride, 2 mM sodium pyrophosphate and 10 mM n-octyl-b-
D-glucopyranoside. After incubation for 15 min on ice, lysates
were centrifuged, and the supernatants were collected and mixed
FIGURE 1 | Dexamethasone inhibits mPGES-1 expression in activated
macrophages in an MKP-1 dependent manner. (A) Effects of dexamethasone
on peritoneal macrophages from wild-type and MKP-1 knock-out (KO) mice.
Cells were incubated with LPS in the presence or absence of dexamethasone
for 24 h. mPGES-1 mRNA levels were measured by quantitative RT-PCR and
normalized against GAPDH mRNA levels. Results are expressed in arbitrary
units, mPGES-1 mRNA levels in unstimulated cells from wild type mice were
set as 1, and the other values were related to that. Results are expressed as
mean + SEM, n = 4. One-way ANOVA with Bonferroni’s post-test was
performed and statistical significance is indicated as ***P < 0.001 and
ns = not significant. #P = 0.0286 vs unstimulated cells from wild-type mice.
(B) Effect of dexamethasone on mPGES-1 mRNA production in J774 murine
macrophages. Cells were stimulated with LPS in the presence or absence of
dexamethasone for 24 h. mPGES-1 mRNA levels were measured by
quantitative RT-PCR and normalized against GAPDH mRNA levels. Results are
expressed in arbitrary units, mPGES-1 mRNA levels in LPS-stimulated cells
were set as 100 % and the other values were related to that. Results are
expressed as mean + SEM, n = 6–7. One-way ANOVA with Bonferroni’s
post-test was performed and statistical significance is indicated as
***P < 0.001. (C) Effect of dexamethasone on mPGES-1 protein expression in
J774 murine macrophages. Cells were stimulated with LPS in the presence or
absence of dexamethasone for 24 h. mPGES-1 protein levels were measured
by Western blot analysis and actin was used as a loading control. Results are
expressed in arbitrary units, mPGES-1 protein levels in LPS-stimulated cells
were set as 100% and the other values were related to that. Results are
expressed as mean + SEM, n = 6. One-way ANOVA with Bonferroni’s
post-test was performed and statistical significance is indicated as
***P < 0.001. Shown is a representative gel of six with similar results.
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FIGURE 2 | Dexamethasone inhibits mPGES-1 expression in acute
inflammatory response in vivo in an MKP-1 dependent manner.
Dexamethasone (2 mg/kg) was given intraperitoneally an hour before LPS (50
µl of 2 mg/ml in PBS) was injected into the hind paw of anesthetized mice to
induce acute inflammation. The paw tissues were collected 6 h after the LPS
injection and mPGES-1 mRNA levels were measured by quantitative RT-PCR
and normalized against GAPDH mRNA levels. Results are expressed in
arbitrary units, mPGES-1 mRNA levels in LPS treated paw tissue from
wild-type mice were set as 100% and the other values are related to that.
Results are expressed as mean + SEM, n = 6–8. One-way ANOVA with
Bonferroni’s post-test was performed and statistical significance is indicated
as *P < 0.05 and ns = not significant.
in a ratio of 1:4 with SDS loading buffer (62.5mM Tris–
HCl, pH 6.8, 10% glycerol, 2% SDS, 0.025% bromophenol
blue and 5% β-mercaptoethanol), and stored at −20◦C until
analyzed.
Equal amounts of protein (10 or 20 µg) were loaded on a
12% SDS-polyacrylamide gel and separated by electrophoresis.
Proteins were transferred to nitrocellulose membranes by dry
electroblotting using iBlot gel transfer stacks and the Invitrogen
iBlot Device according to the manufacturer’s instructions. After
transfer, the membrane was blocked in TBS/T [20 mM Trisbase
(pH 7.6), 150 mM NaCl, 0.1% Tween-20] containing 5%
non-fat milk for 1 h at room temperature. For detection of
phosphorylated proteins, membranes were blocked in TBS/T
containing 5% BSA. Membranes were incubated overnight
at 4◦C with the primary antibody and for 1 h with the
secondary antibody, and the chemiluminescent signal was
detected by ImageQuantTM LAS 4000 mini (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden). The chemiluminescent signal
was quantified with ImageQuant TL 7.0 Image Analysis Software
(GE Healthcare Bio-Sciences AB). Following antibodies were
used in the Western blot analysis: mPGES-1 antibody (AS-
03031; Agrisera AB, Vännäs, Sweden); polyclonal goat anti-rabbit
(sc-2004), actin (sc-1616R) and JNK antibody (#9251; Santa
Cruz Biotechnology, CA, USA), MKP-1 antibody (SAB2500331;
Sigma-Aldrich Inc), p38 MAPK antibody (ab27986; Abcam
plc., Cambridge, UK), phospho-p38 MAPK (#9211) and
phospho-JNK antibody (#9251; Cell Signaling Technology Inc.,
Beverly, MA, USA).
RNA Extraction and Quantitative
Real-Time Reverse Transcription
Polymerase Chain Reaction (qRT-PCR)
At the indicated time points, the culture medium was removed,
and cell homogenization and RNA extraction was carried out
by using GenEluteTM Mammalian Total RNA Miniprep Kit
according to the manufacturer’s instruction. In the case of
paw tissue samples, RNA was extracted with TRIzol reagent.
Briefly, tissue was first homogenized in TRIzol (Thermo Fisher
Scientific, Waltham, MA, USA), and thereafter RNA was
extracted with chloroform and precipitated with isopropanol,
washed with 75% ethanol and resuspended in RNAse free
water. Reverse transcription of the RNA to cDNA was
performed with TaqMan R© Reverse Transcription Reagents
(Applied Biosystems, Foster City, CA, USA) in the case of J774
cells and with Maxima First strand cDNA synthesis kit for RT-
qPCR (Thermo Fisher Scientific) in the case of PM cells and paw
tissue.
Primers and probes were purchased from Metabion
(Martinsried, Germany). Their sequences and concentrations
were optimized according to the manufacturer’s guidelines
in TaqMan Universal PCR Master Mix Protocol part number
4304449 revision C (Applied Biosystems) and were as follows:
mousemPGES-1 CCTGGATACATTTCCTCGTTGTC (forward,
300 nM), GAAGGCGTGGGTTCAGCTT (reverse, 300 nM),
and ACAGGCCGTGTGGTACACACCG (probe, 150 nM);
mouse MKP-1 CTCCTGGTTCAACGAGGCTATT (forward,
300 nM), TGCCGGCCTGGCAAT (reverse, 300 nM), and
CCATCAAGGATGCTGGAGGGAGAGTGTT (probe, 150
nM); mouse GAPDH GCATGGCCTTCCGTGTTC (forward,
300 nM), GATGTCATCATACTTGGCAGGTTT (reverse, 300
nM) and TCGTGGATCTGACGTGCCGCC (probe, 150 nM).
Quantitative PCR was carried out by using TaqMan Universal
PCR Master Mix and ABI Prism 7500 sequence detection
system (Applied Biosystems). The PCR cycling parameters were
incubation at 50◦C for 2 min, incubation at 95◦C for 10 min,
40 cycles of denaturation at 95◦C for 15 s and annealing and
extension at 60◦C for 1 min. A standard curve method was
used to estimate the relative mRNA levels. When calculating the
results, mPGES-1 andMKP-1 mRNA levels were first normalized
against GAPDH.
Statistics
Results are expressed as mean + standard error of the mean
(SEM). One-way ANOVA with Bonferroni’s post-test was
performed using GraphPad InStat version 3.10 for Windows.
Differences were considered significant at *P < 0.05, **P < 0.01
or ***P < 0.001.
RESULTS
Expression of mPGES-1 in unstimulated macrophages from
MKP-1 deficient mice was elevated as compared to macrophages
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FIGURE 3 | Dexamethasone enhances MKP-1 expression in macrophages. (A) Effect of dexamethasone on MKP-1 mRNA expression in J774 murine macrophages.
Cells were stimulated with LPS in the presence or absence of dexamethasone for 1 h. MKP-1 mRNA levels were measured by quantitative RT-PCR and normalized
against GAPDH mRNA levels. Results are given in arbitrary units, MKP-1 mRNA levels in LPS-stimulated cells were set as 100% and the other values were related to
that. Results are expressed as mean + SEM, n = 11–12. One-way ANOVA with Bonferroni’s post-test was performed and statistical significance is indicated as
***P < 0.001. (B) Effect of dexamethasone on MKP-1 protein expression in J774 murine macrophages. Cells were stimulated with LPS in the presence or absence of
dexamethasone for 1 h. MKP-1 protein levels were measured by Western blot analysis and actin was used as a loading control. Results are expressed in arbitrary
units, MKP-1 protein levels in LPS-stimulated cells were set as 100% and the other values were related to that. Results are expressed as mean + SEM. n = 9.
One-way ANOVA with Bonferroni’s post-test was performed and statistical significance is indicated as ***P < 0.001. Shown is a representative gel of nine with similar
results. (C) Effect of dexamethasone on MKP-1 mRNA production in peritoneal macrophages from wild-type mice. Cells were stimulated with LPS in the presence or
absence of dexamethasone for 1 h. MKP-1 mRNA levels were measured by quantitative RT-PCR and normalized against GAPDH mRNA levels. Results are expressed
in arbitrary units, MKP-1 mRNA levels in LPS-stimulated cells were set as 100% and the other values were related to that. Results are expressed as mean + SEM,
n = 5. One-way ANOVA with Bonferroni’s post-test was performed and statistical significance is indicated as ***P < 0.001.
from wild-type mice (Figure 1A). A noticeable increase in
the expression level was seen following stimulation with
LPS both in mouse peritoneal macrophages (Figure 1A)
and in J774 macrophage cell line (Figures 1B,C). Incubation
with dexamethasone significantly downregulated mPGES-
1 expression in both LPS-stimulated J774 macrophages
(Figures 1B,C) and in peritoneal macrophages from wild-type
mice (Figure 1A).
In contrast, incubation with dexamethasone had no effect on
LPS-induced mPGES-1 expression in peritoneal macrophages
from MKP-1 deficient mice (Figure 1A). This suggests that
MKP-1 has an essential role in mediating the suppression by
dexamethasone of mPGES-1 expression in inflammation.
We next investigated whether MKP-1 could mediate the
attenuation by dexamethasone of mPGES-1 expression also
under in vivo conditions. To do this, the effect of dexamethasone
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FIGURE 4 | Dexamethasone inhibits the phosphorylation of MAP kinases p38
and JNK in activated J774 macrophages. (A) Effect of dexamethasone on p38
phosphorylation. J774 macrophages were preincubated with dexamethasone
for 1 h and stimulated with LPS for 30 min. p38 and phosphorylated p38
(pp38) protein levels were measured by Western blot analysis and the levels of
(Continued)
FIGURE 4 | Continued
phosphorylated p38 were normalized against the levels of total p38. Results
are expressed in arbitrary units, phosphorylated p38 levels in LPS-stimulated
cells were set as 100% and the other values were related to that. Results are
expressed as mean + SEM, n = 4. One-way ANOVA with Bonferroni’s
post-test was performed and statistical significance is indicated as
***P < 0.001 and ns = not significant. Shown is a representative gel of four
with similar results. (B) Effect of dexamethasone on JNK phosphorylation.
J774 macrophages were preincubated with dexamethasone for 1 h and
stimulated with LPS for 30 min. JNK and phosphorylated JNK (pJNK) protein
levels were measured by Western blot analysis and the levels of
phosphorylated JNK were normalized against the levels of total JNK. Results
are expressed in arbitrary units, phosphorylated JNK levels in LPS-stimulated
cells were set as 100% and the other values were related to that. Results are
expressed as mean + SEM, n = 6. One-way ANOVA with Bonferroni’s
post-test was performed and statistical significance is indicated as **P < 0.01,
***P < 0.001 and ns = not significant. Shown is a representative gel of six with
similar results.
treatment on mPGES-1 expression in paw inflammation in wild-
type and MKP-1 deficient mice was examined. Dexamethasone,
in a dose (2 mg/kg intraperitoneally) that inhibited the
concurrent paw edema (by 44%; P < 0.05) in wild-type but
not in MKP-1 deficient mice, significantly reduced mPGES-
1 expression in LPS-treated paw tissue in wild-type mice. In
support of the in vitro data, dexamethasone had no effect
on mPGES-1 expression levels in the paw tissue in MKP-
1 deficient mice (Figure 2). To confirm that dexamethasone
could stimulate MKP-1 expression in macrophages, MKP-1
mRNA and protein levels in J774 cells were measured. MKP-
1 expression was low in unstimulated cells but it was increased
by LPS. Furthermore, dexamethasone enhanced MKP-1 mRNA
(Figure 3A) and protein (Figure 3B) levels in J774 macrophages
both in the absence and in the presence of LPS. Dexamethasone
likewise enhanced MKP-1 expression in unstimulated and
LPS-stimulated peritoneal macrophages from wild-type mice
(Figure 3C).
Because MKP-1 has been reported to inactivate p38 and JNK
MAP kinases through dephosphorylation (Franklin and Kraft,
1997; Franklin et al., 1998; Kassel et al., 2001; Abraham et al.,
2006; Chi et al., 2006; Zhao et al., 2006; Turpeinen et al., 2010,
2011; Comalada et al., 2012), the effects of dexamethasone on the
levels of phosphorylated p38 and JNK in activated macrophages
were investigated. Exposure to LPS caused a rapid increase in p38
and JNK phosphorylation in J774 macrophages (Figures 4A,B)
and inmouse peritoneal macrophages (Figures 5A,B). This effect
was reduced by dexamethasone in J774 cells (Figures 4A,B) and
in peritoneal macrophages from wild-type mice (Figures 5A,B).
The role of MKP-1 in the dexamethasone effect was confirmed by
the finding that dexamethasone did not reduce the LPS-enhanced
levels of phosphorylated p38 (Figure 5A) or JNK (Figure 5B) in
peritoneal macrophages fromMKP-1 deficient mice.
Furthermore, the JNK inhibitor SP600125 (Bennett et al.,
2001; Nieminen et al., 2006) but not the p38 inhibitor SB203580
(Cuenda et al., 1995; Shi et al., 2015) reduced LPS-induced
mPGES-1 expression in a manner comparable to that of
dexamethasone (Figures 6A,B).
Together, these data suggest that dexamethasone reduces
mPGES-1 expression in classically activated macrophages in
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FIGURE 5 | Dexamethasone inhibits the phosphorylation of MAP kinases p38
and JNK in activated macrophages in an MKP-1 dependent manner. (A) Effect
of dexamethasone on p38 phosphorylation. Peritoneal macrophages from
wild-type and MKP-1 knock-out (KO) mice were preincubated with
dexamethasone for 1 h and stimulated with LPS for 30 min. p38 and
phosphorylated p38 (pp38) protein levels were measured by Western blot and
the levels of phosphorylated p38 were normalized against the levels of total
p38. Results are expressed in arbitrary units, phosphorylated p38 levels in
LPS-stimulated cells were set as 100 % and the other values were related to
that. Results are expressed as mean + SEM, n = 9. One-way ANOVA with
Bonferroni’s post-test was performed and statistical significance is indicated
as ***P < 0.001 and ns = not significant. Shown is a representative gel of nine
with similar results. (B) Effect of dexamethasone on JNK phosphorylation.
Peritoneal macrophages from wild-type and MKP-1 knock-out (KO) mice were
pre-incubated with dexamethasone for 1 h and stimulated with LPS for
30min. JNK and phosphorylated JNK (pJNK) protein levels were measured by
Western blot analysis and the levels of phosphorylated JNK were normalized
against the levels of total JNK. Results are expressed in arbitrary units,
phosphorylated JNK levels in LPS-stimulated cells were set as 100% and the
other values were related to that. Results are expressed as mean + SEM,
n = 5. One-way ANOVA with Bonferroni’s post-test was performed and
statistical significance is indicated as ***P < 0.001 and ns = not significant.
Shown is a representative gel of five with similar results.
FIGURE 6 | JNK inhibitor SP600125 inhibits the expression of mPGES-1 in
activated macrophages. (A) Effects of a JNK inhibitor (SP600125), a p38
inhibitor (SB203580) and dexamethasone on mPGES-1 mRNA production in
J774 murine macrophages. Cells were incubated with LPS and the
compounds under investigation for 24 h. mPGES-1 mRNA levels were
measured by quantitative RT-PCR and normalized against GAPDH mRNA
(Continued)
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FIGURE 6 | Continued
levels. Results are expressed in arbitrary units, mPGES-1 mRNA levels in
LPS-stimulated cells were set as 100% and the other values were related to
that. Results are expressed as mean + SEM, n = 6–7. One-way ANOVA with
Bonferroni’s post-test was performed and statistical significance is indicated
as ***P < 0.001 and ns = not significant. (B) Effects of a JNK inhibitor
(SP600125), a p38 inhibitor (SB203580) and dexamethasone on mPGES-1
protein expression in J774 murine macrophages. Cells were stimulated with
LPS and the compounds under investigation for 24 h. mPGES-1 protein levels
were measured by Western blot analysis and actin was used as a loading
control. Results are expressed in arbitrary units, mPGES-1 protein levels in
LPS-stimulated cells were set as 100% and the other values were related to
that. Results are expressed as mean + SEM, n = 5–6. One-way ANOVA with
Bonferroni’s post-test was performed and statistical significance is indicated
as ***P < 0.001, **P < 0.01 and ns = not significant. Shown is a
representative gel of five with similar results.
a manner dependent on enhanced MKP-1 expression and
subsequently reduced JNK phosphorylation.
DISCUSSION
Microsomal prostaglandin E synthase-1 is an inducible
inflammatory enzyme, the expression of which has been reported
to be inhibited by glucocorticoids (Stichtenoth et al., 2001; Tuure
et al., 2015). The present study extends the previous data by
showing that the glucocorticoid effect on mPGES-1 is mediated
through enhanced expression of the regulatory phosphatase
MKP-1 and subsequent dephosphorylation of the MAP kinase
JNK in inflammatory conditions.
MKP-1 deficient mice have a normal phenotype in resting
conditions but they develop enhanced responses in inflammatory
states. For example, they have impaired tolerance against
bacterial endotoxin and when exposed to LPS, significantly
higher levels of cytokines and other inflammatory factors are
released and the inflammatory response is much more severe
as compared to wild-type controls (Chi et al., 2006; Hammer
et al., 2006; Zhao et al., 2006; Korhonen et al., 2011; Turpeinen
et al., 2011). Those findings support a significant role for MKP-
1 as an endogenous factor regulating and limiting excessive
inflammatory responses and as a potential target to be increased
with anti-inflammatory treatments. In the present experiments
with cells from wild-type and MKP-1 deficient mice, we found
that MKP-1 mediates the suppression by dexamethasone of
mPGES-1 expression in activated macrophages. This effect was
also translated to in vivo conditions, as dexamethasone reduced
mPGES-1 expression in inflamed paw tissue in wild-type but
not in MKP-1 deficient mice. Dexamethasone also suppressed
inflammatory edema in wild-type but not in MKP-1 deficient
mice. Although this is dependent on several inflammatory factors
(Naidu et al., 2010; Zar et al., 2014; Chen et al., 2016), the reduced
mPGES-1 expression may contribute to the anti-inflammatory
effect of dexamethasone because mPGES-1 inhibitors have been
reported to attenuate inflammatory paw edema in experimental
models (Koeberle et al., 2009; Siemoneit et al., 2011).
In addition to its suppressive effect on mPGES-1,
dexamethasone augmented the expression of MKP-1 when
introduced to wild-type cells in the absence or in the presence
of LPS, as shown also earlier (Abraham et al., 2006; Shipp et al.,
2010; Zhu et al., 2010; Prabhala et al., 2016; Keränen et al., 2017).
MKP-1 is an early response gene, the expression of which is
transiently increased following exposure to inflammatory and
cellular stress factors (Owens and Keyse, 2007; Boutros et al.,
2008; Caunt and Keyse, 2013). In addition, MKP-1 promoter
contains glucocorticoid responsive elements (Shipp et al., 2010)
indicating that glucocorticoids may directly enhance MKP-1
transcription. MKP-1 expression is also regulated by various
post-transcriptional mechanisms (Wong et al., 2005; Kuwano
et al., 2008; Korhonen and Moilanen, 2014). As glucocorticoids
have been shown not only to enhance but also to prolong MKP-1
expression (Keränen et al., 2017), they may regulate MKP-1 gene
expression at post-transcriptional level in addition to their direct
transcriptional effect.
MKP-1 regulates the inflammatory responses by inactivating
MAP kinases p38 and JNK through dephosphorylation (Franklin
and Kraft, 1997; Franklin et al., 1998; Chi et al., 2006;
Zhao et al., 2006; Turpeinen et al., 2010, 2011; Comalada
et al., 2012). Therefore, it is interesting that dexamethasone
was found to reduce p38 and JNK phosphorylation in wild-
type but not in MKP-1 deficient macrophages exposed to
inflammatory stimulus. In support of our data, Abraham
and co-workers reported that dexamethasone inhibits p38
and JNK phosphorylation in murine bone-marrow derived
macrophages (Abraham et al., 2006), whereas in another study
dexamethasone was found to downregulate p38 but not JNK
or ERK phosphorylation (Bhattacharyya et al., 2007). These
findings show that the glucocorticoid-induced enhancement in
MKP-1 expression has functional consequences at the level of
reduced MAP kinase phosphorylation, which is likely to result
in deactivation of these inflammatory pathways possibly by a
cell-type dependent manner.
The present findings provide support for MAP kinase JNK
being a seminal downstream factor regulating the expression
of mPGES-1 under inflammatory conditions in macrophages:
dexamethasone was found to reduce the phosphorylation of both
p38 and JNK kinases along with its stimulatory effect on MKP-
1 expression. However, the JNK inhibitor but not p38 inhibitor
attenuated the expression of mPGES-1. That is supported by
the findings in human gingival fibroblasts (Yucel-Lindberg
et al., 2006; Båge et al., 2010), in rat neonatal cardiomyocytes
(Degousee et al., 2006) and inmurine microglial cells (de Oliveira
et al., 2008; He et al., 2016) in which JNKwas found to be involved
in the regulation of mPGES-1 expression. The effect may be cell
type dependent because in human osteoarthritic chondrocytes
stimulated with IL-1β, MAP kinases p38 and ERK had a crucial
role in the regulation of mPGES-1 expression, whereas JNK was
insignificant (Masuko-Hongo et al., 2004).
In inflammation, various pro-inflammatory cytokines and
bacterial products are known to enhance mPGES-1 expression.
The transcriptional mechanisms are not known in detail, but
early growth response protein 1 (EGR-1) and nuclear factor
kappa B (NF-kB) have been identified as key transcription factors
for mPGES-1 (Koeberle and Werz, 2015). Activator protein 1
(AP-1) is one of the additional factors reported to be involved
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in the transcriptional activation of mPGES-1 (Moon et al., 2005;
Jungel et al., 2007). This observation is relevant in the light of the
present results because AP-1 is activated by JNK. Expression of
mPGES-1 may also be regulated by JNK at post-transcriptional
level as a JNK inhibitor has been found to destabilize mPGES-1
mRNA and reduce mPGES-1 protein levels in murine neonatal
cardiomyocytes (Degousee et al., 2006). However, additional
studies are needed to clarify the detailed mechanisms of how JNK
regulates mPGES-1 expression.
In conclusion, dexamethasone was found to down-regulate
mPGES-1 expression in classically activated macrophages
through increased expression of the regulatory phosphatase
MKP-1 and subsequently decreased phosphorylation of the MAP
kinase JNK. These results extend the previous understanding
of the molecular mechanisms regulating mPGES-1 expression
in inflammatory conditions. The findings also highlight the
potential of MKP-1 as an anti-inflammatory drug target.
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